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Summary p53 gene aberrations are common in human malignancies, and recent studies suggest that in
cervical carcinoma p53 function is inactivated either by complex formation with human papillomavirus (HPV)
E6 product or by gene mutation. Using polymerase chain reaction (PCR) followed by denaturing gradient gel
electrophoresis (DGGE), we examined the mutational status of the four 'hotspot' regions of the p53 gene in 47
primary cervical carcinomas. HPV status was determined, also by PCR. In 20 of these cases, we examined for
loss of heterozygosity (LOH) on chromosome l7pl3. In the 47 carcinomas, and in a further 68 biopsy
specimens from normal, premalignant and malignant cervix, we investigated aberrant immunocytochemical
expression of p53. Immunocytochemically, abnormal p53 expression was detected in 13 of 115 cases (8/57
carcinomas). Somatic mutation in p53 was detected in 1 of 47 cervical carcinomas; 36 were positive for HPV
16, 18 or 33. A low level of allele loss (3 out of 20 cases) was detected on chromosome 17p, occurring in both
HPV-positive and HPV-negative cases, and in cases with and without p53 mutations. We conclude that
somatic mutation in the hotspot regions of the p53 gene occurs infrequently in cervical carcinomas; that
immunocytochemically detectable levels of p53 are also infrequent; and that there is no consistent correlation
between p53 mutational status, LOH on chromosome 17p or HPV status in these cancers.
Loss of function of the p53 tumour-suppressor gene has now
been implicated in a wide variety of human malignancies.
For example, allele losses on the short arm of chromosome
17 in the region of the p53 gene (17pl3.1) have been demon-
strated in 60% of breast carcinomas (Mackay et al., 1988;
Devilee et al., 1989), 50-60% of ovarian epithelial car-
cinomas (Eccles et al., 1990; Russell et al., 1990), over 70%
of osteosarcomas (Toguchida et al., 1989), 55% of astro-
cytomas (Fults et al., 1989), 63% of bladder carcinomas
(Tsai et al., 1990), 75% of colonic carcinomas (Vogelstein et
al., 1988) and up to 100% of small-cell lung carcinomas
(Mori et al., 1989). Somatic mutations in the p53 gene have
also been found in a substantial proportion of tumour types,
and these may or may not be associated with allele losses in
the region of p53 on chromosome 17p (Nigro et al., 1989;
Chiba et al., 1990; Eccles et al., 1992). Over 80% of the
somatic mutations identified in the p53 gene have been found
to cluster in four 'hotspot' regions A-D (HSRs A-D), that
coincide with the evolutionarily most highly conserved
regions of the gene (Nigro et al., 1989).
Monoclonal antibodies have been developed for the detec-
tion of p53 gene products by immunocytochemical means,
using frozen or formalin-fixed paraffin-embedded tissues
(Banks et al., 1986; Midgley et al., 1992; Vojtesek et al.,
1992). As the half-life of the wild-type protein is extremely
short, and the stability of the mutant form is increased, it is
generally assumed that any p53 product detected immuno-
histochemically represents the mutant form (Lane & Ben-
chimol, 1990). False positives, resulting from non-mutational
stabilisation of the protein, and possibly involving interrup-
tion to the normal degradative pathway, have been identified
in cell lines (Wynford-Thomas, 1992), but the incidence of
such genuine false positives in human tumours is not yet
clear.
Only a few studies have examined the status of p53 in
cervical carcinoma, but recent data have suggested it may
have an important role (Crook et al., 1991a, 1992; Fujita et
al., 1992; Kaelbling et al., 1992). There are plausible
theoretical grounds for the proposition that p53 alterations
may act in combination with human papillomaviruses (HPV),
which have long been associated with cervical carcinogenesis
(Bosch & Munoz, 1989; zur Hausen, 1989). The HPV E6-
and E7-encoded oncoproteins are believed to form complexes
with the products of p53 and Rb genes respectively (Banks et
al., 1990; Scheffner et al., 1991), conferring growth advantage
through inhibition of p53 (and Rb) activity (O'Rourke et al.,
1990). The formation of complexes between HPV E6 and p53
proteins has been shown, in vitro, to result in targeting ofp53
for degradation, through a ubiquitin-dependent proteolysis
system (Scheffner et al., 1991), and hence to low levels of p53
protein (perhaps not immunocytochemically detectable) in
the cell. Interaction between p53 and HPV 16 E7 has also
been demonstrated, in studies showing that expression of
wild-type p53 suppresses the immortalising activity of HPV
16 E7, whereas mutated murine p53 potently enhances its
transforming activity in rodent systems (Crook et al., 1991b).
Sequencing of p53 DNA and mRNA, from cervical car-
cinoma tissue and cell lines respectively, revealed wild-type
p53 in those that were HPV positive, whereas the mutated
form was demonstrated only in those that were HPV
negative (Crook et al., 1991a, 1992). This led to the sugges-
tion that inactivation of p53 function, either by mutation or
by complexing with HPV gene product, is central to carcino-
genesis in the cervix.
In this study, we have examined p53 function by three
principal techniques. Firstly, we screened for the presence of
aberrant p53 expression in 115 cervical biopsy specimens
(including 57 invasive carcinomas) using an immunohisto-
chemical technique. Secondly, in 47 of the 57 carcinomas, we
investigated the incidence of mutations in the four recognised
mutational 'hotspots' A-D and in a fifth region encoding
amino acids 193-218 of the p53 gene, using a combined
polymerase chain reaction (PCR)/denaturing gradient gel
electrophoresis (DGGE) technique (Sheffield et al., 1989;
Borresen et al., 1991). Thirdly, in 20 of the carcinomas, we
determined the frequency of allele loss on chromosome 17p,
in the vicinity of the p53 gene. Where sufficient material was
available (47 carcinomas), the HPV status (types 16, 18 and
33) was also determined, to correlate with the results of p53
analyses.
Materials and methods
Cervical biopsy specimens
Fresh specimens of cervical tissue were obtained from
patients undergoing hysterectomy or radiotherapy, who gave
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informed consent for its use in this study. Specimens of
tumour tissue were 'snap frozen' in liquid nitrogen. Cryostat
sections were cut for haematoxylin and eosin staining to
confirm tumour presence, and non-neoplastic tissue was trim-
med from the frozen tissue block before DNA extraction.
Blocks which included less than 70% neoplastic cells were
not used for DNA extraction. Fixed specimens were obtained
from the archives of the Edinburgh University Pathology
Department.
p53 immunocytochemistry
Four-micron sections from 115 cervical biopsy specimens
(including 57 invasive cervical carcinomas), fixed in either
formalin or periodate-lysine-paraformaldehyde-dichromate
(PLPD) (Pollard et al., 1987), and histologically distributed
as in Table I were used. An avidin-biotin (AB) complex
method was employed, with human p53-specific mouse
monoclonals PAb 1801 (Cambridge Bioscience) and MAb
DO-7 (a gift from Professor D. Lane, CRC Laboratories,
Dundee, UK) as primary antibodies. Both antibodies recog-
nise wild-type and mutated p53 but recognise different
epitopes. The epitope recognised by PAb 1801 probably lies
between amino acids 1 and 91 of the p53 protein, while that
recognised by MAb DO-7 lies between amino acids 1 and 45,
and probably between amino acids 37 and 45 (Vojtesek et al.,
1992). Biotinylated rabbit anti-mouse antiserum (1:250) was
used as secondary antibody, AB complex as final stage, and
diaminobenzidine for visualisation. PAb 1801 (1:100) was
used on PLPD-fixed tissue only; MAb DO-7 (1:250 formalin
fixed; 1:1,000 PLPD fixed) was used on all specimens. In
each run, a section of a colonic adenocarcinoma known from
previous sequencing experiments to contain a mutation of the
p53 gene was included as a positive control. For each case,
negative control sections were made in which primary
antibody was omitted but all other steps performed as for
test sections.
Analysis ofp53 mutations
The GC-clamped PCR primers and the method used to
amplify across the 'hotspot' regions A-D (codons 128-153,
155-185, 237-253 and 265-301 respectively) ofthe p53 gene
were modified in the following ways from those previously
described by Borresen et al. (1991): 500 ng ofcervical tumour
DNA was used as template in 100 ll reactions; a fifth pair of
GC-clamped primers (for convenience designated the 'E'
primers) was used to amplify the non-primer region corre-
sponding to codons 193-218 of exon 6.
PCR products from 47 cervical carcinomas (a sUbset of the
57 included in the p53 immunocytochemical analysis) were
subjected to electrophoresis on 3% agarose gels containing
ethidium bromide; and the presence of amplified product was
confirmed by UV transillumination of the gel. Products were
then screened for p53 mutations by parallel DGGE (30-80%
denaturing gradient polyacrylamide/55°C) with those from
previously sequenced ovarian and colonic carcinomas, known
to possess p53 mutations in regions A, B, C, D or E, as
Table I Histological diagnosis of 115 cervical specimens studied
Histology No. of cases
Squamous carcinoma 51
Adenocarcinoma 3
Adenosquamous carcinoma 3
CIN3 46
CINI or 2 24
Glandular atypia/adenocarcinoma in situ 3
Benign metaplastic changes in glands 9
Normal squamous epithelium 53
Normal endocervical glands 62
Note: Multiple histological appearances were present in many
specimens.
positive controls. Detected mutations were characterised by
conventional DNA sequencing of PCR products amplified
from the tumour and corresponding constitutional (blood)
DNA.
Allele loss analysis
Six polymorphic DNA probes were radiolabelled and used in
restriction fragment length polymorphism (RFLP) analysis to
compare tumour and constitutional genotypes of 20 cervical
carcinoma patients, for detection of LOH, as previously de-
scribed (Busby-Earle et al., 1993). Aliquots of 10jig of paired
tumour/blood DNA samples were digested with appropriate
restriction endonucleases, size fractionated on 0.8% agarose
gels, and Southern blotted onto Hybond-N membranes,
which were used in hybridisation reactions (65°C/16 h), prior
to autoradiography, as previously described (Busby-Earle et
al., 1993). These 20 cases formed a subset of the 47 cases
analysed for p53 mutations, described above.
HPV analysis
The method used has been detailed elsewhere (Busby-Earle et
al., 1993). Briefly, primers specific for the E6 gene of HPV 6,
11, 16, 18 and 33 (Arends et al., 1991) were used to set up
standard 100,lI PCR reactions, containing 500 ng oftemplate
(cervical carcinoma DNA) and 2.5pl of Taq polymerase
(Northumbria Biologicals). Thirty-two to thirty-five cycles of
denaturation (94°C) (1 min), annealing (55°C for HPV 6/16
or 50°C for HPV 11/18/33) (2 min) and extension (72C)
(3 min) were preceded by a 1.5 min denaturation and ended
with a 10 min extension. Products were detected as described
above for p53. Plasmids containing the appropriate HPV
sequence were used as positive controls; and the labelled
insert was used in Southern blotting analyses to detect the
integrated or episomal status of HPV in 12 specimens.
Results
p53 immunocytochemistry
The two antibodies employed, PAb 1801 and MAb DO-7,
produced specific nuclear staining in the positive control
colonic carcinoma tissue, while normal colonic mucosa was
negative (Figure 1). Antibody DO-7 produced superior stain-
ing to PAb 1801, being crisper and more intense, although
the distribution of positively stained cells was similar.
Positive p53 staining was found in 13 out of 115 cervical
biopsy specimens, including eight of the 57 carcinomas
Figure 1 Immunohistochemical staining with p53 antibody MAb
DO-7 in a section from a PLPD-fixed positive control colonic
carcinoma known to possess mutated p53. Clear nuclear localisa-
tion of stain is seen in cells of malignant colonic epithelium (m),
but adjacent normal colonic epithelium (n) is negative.734 R.M.C. BUSBY-EARLE et al.
examined. In each case, staining was focal in distribution,
with only a minority of positive nuclei, in a background of
entirely negative cells (Figure 2). Details ofpositively staining
carcinomas are shown in Table II. Sparse positive nuclear
staining was also seen in three cases with dysplastic
squamous epithelium (CIN2 or CIN3), and two cases with
normal endocervical glands.
pS3 mutations
In each of five positive controls (ovarian and colonic car-
cinomas), amplification of the region in which a p53 muta-
tion had previously been identified yielded a product which,
on denaturing gradient gel electrophoresis (DGGE), migrated
at a different rate from its unmutated counterpart (constitu-
tional blood DNA).
For 46 of the 47 cervical carcinomas examined, PCR
amplification of each of the p53 'hotspot' regions (HSRs)
A-D revealed a single band with the same DGGE mobility
as that of the normal or constitutional DNA, indicating the
absence of mutations. Only one cervical carcinoma (a stage
IVa, HPV-negative, squamous carcinoma from a 54-year-old
patient) revealed a mutant band in the HSR B region
(codons 155-185 of exon 5) (Figure 3). This migrated at a
slower rate than its normal counterpart, and could not be
detected in the constitutional (blood) DNA. Subsequent
sequencing of the PCR product from tumour DNA from this
region confirmed the presence of a CGC-*TGC transition at
codon 175, resulting in substitution of cysteine for
arginine.
Of the 47 carcinomas examined with the 'E'-region
primers, two produced amplified fragments that migrated at
a different rate from their normal counterpart (Figure 4).
Comparison with constitutional (blood) DNA from the cor-
responding individuals revealed the presence of a
CGA+CGG transition at codon 213. This is a silent muta-
tion, as both sequences encode arginine. One of these two
patients was HPV negative, while the other was positive for
HPV 16.
Among the eight cervical carcinomas displaying immuno-
cytochemical p53 positivity, only two showed mutations, and
of these only one was somatic. Conversely, of the three
tumours in which p53 mutations were detected, two showed
immunohistochemical positivity with one or both
antibodies.
Chromosome 17p allele losses
The results of 71 informative RFLP analyses of constitu-
tional vs tumour DNA for 20 cervical carcinomas using six
a
56 1
Known
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b
Tumour
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Figure 2 Immunohistochemical staining with p53 antibody MAb
DO-7 in a section from a PLPD-fixed cervical carcinoma (an
HPV 16-positive squamous carcinoma). Positive nuclear staining
is present in malignant cells of the squamous carcinoma (c), seen
here invading a lymphatic space (arrowed).
Figure 3 a, DGGE of PCR-amplified products of HSR B
(codons 155-185 of exon 5) of the p53 gene in cervical tumours
and a positive control. Patient no. 56 shows a mutant band
similar to that of the known mutant standard in the adjacent
track. (Heteroduplex bands are also seen.) Single bands from
other cervical carcinomas without mutations are seen in the other
four unlabelled tracks. b, Tumour DNA from patient no. 56
shows a mutant band which is absent from the constitutional
(blood) DNA in the adjacent track.
Table II Features of eight cervical squamous carcinomas showing immunohisto-
chemical p53 positivity
Histological
FIGO stage grade' HPV status p53 mutation
Ilb 2 16 Absent
IIb 2-3 16 Codon 213 - CGA-CGG (silent)
lb 3 Negative Absent
Ib 3 18 Absent
Ib 3 Negative Absent
Ilb 3 16 Absent
IVa 3 Negative Codon 175 - CGC-TGC
IlIb 2 16 Absent
'a, well differentiated; 2, moderately differentiated; 3, poorly differentiated.p53 IN CERVICAL CARCINOGENESIS 735
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Figure 4 DGGE of the 'E' primer amplified fragments (codons
193-218 of exon 6) of the p53 gene in cervical tumour and its
corresponding blood (constitutional) DNA from patient no. 55,
and DNA from cervical tumour patient no. 52. The presence of
four distinct bands in both the tumour and blood DNA of
patient no. 55 suggests the presence of a constitutional polymor-
phism rather than a mutation. A normal band (neither polymor-
phism nor mutation present) is seen in patient no. 52.
polymorphic markers on chromosome 17p have previously
been reported (Busby-Earle et al., 1993). For each of the six
markers at least nine and up to 15 cases were informative.
Five of the six markers revealed loss of heterozygosity
(LOH). The prevalence of LOH amongst informative cases
ranged from 0/15 (0%) for C3068 to 1/9 (11%) for pBHP 53.
The combined result with six RFLP markers demonstrated
that LOH occurred at one or more loci on chromosome 17p
in 3 of 20 (15%) informative cases; no losses occurred in the
remaining 17 tumours.
There were no detectable clinical or pathological
differences between the three tumours demonstrating LOH
(all squamous carcinomas) and those that did not. There was
no correlation between the allele losses observed and the
presence or integration of HPV; and the single tumour
demonstrating allele loss with the probe pBHP 53 (tumour
14) was negative for all five HPV types examined.
HPV analysis
As detailed elsewhere (Busby-Earle et al., 1993), HPV 16, 18
or 33 was detected in 75% (15/20) of 20 cervical carcinomas
examined; five (25%) were negative for all HPV types tested,
and none contained HPV 6 or 11. The viral genome was
found to be integrated in 9 of the 12 HPV-positive cases
analysed. In these cases, neither viral presence nor its integra-
tion correlated with p53 expression or mutational status. In
the remaining 27 cervical carcinomas tested, it was not pos-
sible, because of limited DNA availability, to examine for
integrated vs episomal status with respect to HPV. Further-
more, given the results of the first 20 cases, their status with
respect to HPV 6 and 11 was not determined. Overall, 36 of
the 47 cervical carcinomas examined were positive for HPV
16, 18 or 33 and 11 were negative for all three types.
Of the two cervical carcinomas in which the silent
(CGA-* CGG transition) p53 mutation was detected, one
was negative for the five HPV types examined, while the
other was positive for HPV 16. Of the other ten HPV-
negative tumours, in which all five p53 regions had been
successfully amplified, only one (the tumour in which a
CGC-.*TGC transition was detected in HSR B) revealed p53
mutation on DGGE screening.
Of the eight cervical carcinomas exhibiting p53
immunocytochemical positivity, four were positive for HPV
16 and one for HPV 18 and three were negative for the
various HPV types tested.
Discussion
In this study, we investigated p53 gene alterations in primary
cervical carcinomas using three different approaches: muta-
tional status of the p53 gene; LOH at the p53 gene locus on
chromosome 17p; and demonstration of aberrant immuno-
cytochemical expression of p53 in tissue sections. We sought
correlations between p53 alterations and HPV status of
tumours.
Immunocytochemical detection of p53 protein was infre-
quent both in cervical carcinoma and in its preinvasive
phases. This contrasts with reported findings in a range of
other common tumours (Bartek et al., 1991), especially breast
(Cattoretti et al., 1988), lung (Iggo et al., 1990), ovary (Eccles
et al., 1992), colon (Purdie et al., 1991) and skin (L. Stark,
personal communication), in which high levels of p53 protein
expression are common. In breast (Davidoff et al., 1991) and
endometrial (Kohler et al., 1992) carcinoma, a good correla-
tion has been found between p53 expression and advanced
disease. In this series, positive nuclear staining was present in
only 13 out of 115 cervical biopsies (8 of 57 carcinomas), and
was sparse in comparison with positive controls. Staining
occurred in benign, premalignant and malignant lesions, and
rather than indicating mutation in the p53 gene its presence
may reflect increased p53 expression in cells undergoing
DNA repair (Lane, 1992).
A further distinction from other common solid tumours
was the frequency with which mutations were found in 'hot-
spot' regions of the p53 gene. Out of 47 invasive cervical
carcinomas analysed, only one somatic mutation (in an HPV-
negative tumour) was found in the four mutationally active
'hotspot' regions. The mutation occurred at codon 175, re-
sulting in an arginine + cysteine transition, which has not
previously been reported at this codon (Caron de Fromentel
& Soussi, 1992). In two other cervical carcinomas (one HPV
16 positive and the other HPV negative), the apparent muta-
tions detected in the 'E' region were also present in the
corresponding constitutional DNA samples. On sequencing
these were each found to be silent mutations at codon 213,
thus constituting a normal polymorphism. It is notable that
in 9 out of the 11 HPV-negative cervical carcinomas, no
mutations were detected in any of the five p53 regions
examined.
The technique of constant denaturing gradient gel electro-
phoresis (Borresen et al., 1991) is a rapid and reliable method
of screening for mutations in the 'hotspot' regions of the p53
gene, and detected all mutations present in positive controls
with no false positives. Regions A-E examined in this study
cover 89% of the mutations which have so far been detected
(Caron de Fromentel & Soussi, 1992). It is possible that by
screening a wider area of the gene a few more mutations
might have been demonstrated, but in studies of cervical
carcinomas and derived cell lines in which the entire coding
region of the p53 gene has been sequenced the mutations
found have only occurred in regions A-D (Crook et al., 1991b,
1992). Our findings were in agreement with those recently
reported by Helland et al. (1993), who, using a similar tech-
nique, found only two mutations of the p53 gene (one of
which was silent) in a series of 92 cervical carcinomas.
Although not every mutation in the p53 gene may lead to
accumulation of the protein (Wynford-Thomas, 1992), it has
been suggested that if p53 protein is demonstrated
immunohistochemically it is likely to be mutant (Lane &
Benchimol, 1990). In this series in which extremely sparse
p53 expression in a minority (8/47) of cases was observed,
there was a virtual absence of p53 mutations in the four
HSRs. However, in the single carcinoma in which a somatic
mutation did occur, sparse p53 protein expression was
observed with antibody MAb DO-7. In the two tumours with
silent mutations at codon 213, one showed similar sparse
accumulation of p53 protein product while the other did not.
Therefore, in this series, no clear-cut correlation could be
demonstrated between immunocytochemical detection of p53
and the occurrence of p53 mutations.
In other neoplasms, mutation in one p53 allele is fre-736 R.M.C. BUSBY-EARLE et al.
quently accompanied by loss of the corresponding normal
allele (Baker et al., 1990; Iggo et al., 1990; Prosser et al.,
1990; Eccles et al., 1992). By contrast, the cervical car-
cinomas in this series showed a relatively low frequency of
LOH on chromosome 17p (15%), within the range expected
as 'background' for any gene locus examined, and in keeping
with the relative absence of p53 mutations. Moreover, in the
three cases showing allele loss, no mutations were detected in
the remaining allele in the four 'hotspot' regions suggesting
these may have occurred as a consequence of the general
genetic instability exhibited by many tumours. These findings
are in keeping with those of Helland et al. (1993), who
reported allelic imbalance in 11 out of 52 informative cases
(22%) at the p53 locus.
Other recent studies have suggested that inactivation of
p53 function is fundamental to cervical carcinogenesis
(Crook et al., 1991a, 1992). It has been proposed that inac-
tivation of the gene product may occur either by p53 gene
mutation in HPV-negative tumours, or by complexing with
the HPV E6 transforming gene product in HPV-positive
tumours. In our studies, only 1 of 11 HPV-negative car-
cinomas showed evidence ofa somatic mutation in any of the
four mutational 'hotspots' of the p53 gene. However, we
screened only for HPV types 16, 18 and 33, most commonly
associated with cervical cancer, and we cannot exclude the
possibility that some negative cases may have been positive
for other less common high-risk virus types. Our findings are
consistent with those of Helland et al. (1993), who found no
mutations in the p53 gene in all four of their HPV-negative
patients.
If increased p53 expression in benign, premalignant and
malignant lesions reflects DNA repair, it is surprising that it
was so rarely observed. Inactivation of p53 may occur by
interaction with the HPV E6 gene product, and it is possible
that elevated expression of p53 detected
immunocytochemically in HPV-positive tumours could reflect
lack of E6 gene expression in these tumours. Other possible
mechanisms of p53 inactivation such as alteration in mdm-2
gene expression have not been addressed in this study. The
product of the mdm-2 oncogene binds wild-type p53 in vitro
(Oliner et al., 1992), and it is possible that its increased
expression may account for p53 accumulation in our
immunocytochemically positive cases.
Overall, our findings suggest that cervical carcinoma differs
from other common neoplasms in the manner in which p53
gene alterations are involved in the carcinogenic process.
Mutations in the highly conserved regions of the gene are
relatively infrequent and no correlation has been found
between p53 mutational status and either LOH on chromo-
some 17p or the presence or integration of HPV 16, 18 or 33.
Finally, the immunohistochemical demonstration of p53 is
not a striking feature in the preinvasive or invasive phases of
the malignancy.
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